Colorectal Cancer Clinical Trial
Official title:
Increasing Colon Cancer Screening in Primary Care Among African Americans
RATIONALE: Screening may help doctors find colorectal cancer sooner, when it may be easier
to treat. Finding out what affects a patient's decision to undergo screening tests may help
increase the number of patients who undergo regular screening for cancer. It is not yet
known whether personalized invitations to undergo colorectal cancer screening are more
effective than standard screening reminders.
PURPOSE: This randomized phase III trial is studying ways to increase colorectal cancer
screening in African Americans.
OBJECTIVES:
- To assess the intervention impact on colorectal cancer (CRC) screening utilization over
a 6-month observation period in African-American participants.
- To assess the intervention impact on CRC screening preference, classified into three
levels (i.e., "decided not to screen or never heard of," "undecided," or "decided to
screen"), based on data obtained from both the endpoint chart audit and the endpoint
survey.
- To assess intervention impact on population health-management representations related
to CRC screening, as assessed by perceived salience and coherence and self-efficacy
related to CRC screening measured with 6 to 10 Likert-type items on both the baseline
and endpoint surveys.
- To analyze intervention cost-effectiveness, from the societal perspective and from the
more limited perspective of the provider and payer, focusing on the average and
incremental cost per additional person who is compliant (i.e., has a CRC screening test
during the observation period) for each alternative intervention and estimate the cost
per life-year saved.
OUTLINE: This is a multicenter study. Participants are stratified according to practice.
Participants are randomized to 1 of 2 intervention arms.
- Arm I (standard-intervention group): Participants receive a personalized screening
invitation letter encouraging selection and performance of one of the screening tests,
a generic colorectal cancer (CRC) screening informational booklet, stool blood testing
(SBT) cards, and instructions for arranging a colonoscopy screening appointment. After
45 days, participants who have not been screened receive a reminder letter.
- Arm II (tailored-navigation intervention group): Participants receive a CRC screening
invitation letter and materials that are tailored to the individual's preferred
screening test strategy (i.e., SBT; SBT and instructions for arranging flexible
sigmoidoscopy, instructions for arranging flexible sigmoidoscopy; or instructions for
arranging colonoscopy). After 30 days, participants who have not been screened will
receive a reminder by telephone. Those participants who have undergone screening will
be congratulated for taking the time and preventative action, and be encouraged to
continue future screenings. After 45 days, participants who have not been screened
receive a reminder letter.
Participants are assessed by a baseline survey consisting of personal background, cognitive
and psychological representations, social support and influence, intention, and decision
stage related to screening SBT and colonoscopy preference. Data obtained from the endpoint
survey assessing whether participants and their providers discussed CRC screening before the
study and opinions about the intervention, and an endpoint chart audit to gather data on
participant CRC screening exam dates and exam results (i.e., screening SBT, flexible
sigmoidoscopy, colonoscopy, double-contrast barium enema [DCBE] x-ray) are assessed for
group differences.
;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |